key: cord-0963515-m98seasv
authors: Phillips, Matthew C.; Sarff, Laura; Banerjee, Josh; Coffey, Chase; Holtom, Paul; Meurer, Steve; Wald‐Dickler, Noah; Spellberg, Brad
title: Effect of mortality from COVID‐19 on inpatient outcomes
date: 2021-09-18
journal: J Med Virol
DOI: 10.1002/jmv.27332
sha: 370b0a922f8380dee925f61e8fd872dfa25c1079
doc_id: 963515
cord_uid: m98seasv

When hospitals first encountered coronavirus disease 2019 (COVID‐19), there was a dearth of therapeutic options and nearly 1 in 3 patients died from the disease. By the summer of 2020, as deaths from the disease declined nationally, multiple single‐center studies began to report declining mortality of patients with COVID‐19. To evaluate the effect of COVID‐19 on hospital‐based mortality, we searched the Vizient Clinical Data Base for outcomes data from approximately 600 participating hospitals, including 130 academic medical centers, from January 2017 through December 2020. More than 32 million hospital admissions were included in the analysis. After an initial spike, mortality from COVID‐19 declined in all regions of the country to under 10% by June 2020 and remained constant for the remainder of the year. Despite this, inpatient, all‐cause mortality has increased since the beginning of the pandemic, even those without respiratory failure. Inpatient mortality has particularly increased in elderly patients and in those requiring intubation for respiratory failure. Since June 2020, COVID‐19 kills one in every 10 patients admitted to the hospital with this diagnosis. The addition of this new disease has raised overall hospital mortality especially those who require intubation for respiratory failure.

Utilizing data compiled from over 600 hospitals across the United States, we evaluate temporal shifts in the number of cases, deaths, and mortality of COVID-19. We then put this new disease in the context of hospital outcomes over the past 4 years. By exploring this data longitudinally, we sought to gain a greater understanding of the changing outcomes of COVID-19 and how this new disease has changed inpatient hospital outcomes nationally.

We searched for mortality, diagnostic, and age information regarding all admission to hospitals participating in the Vizient Clinical Data Base (CDB) from January 2017 through December 2020. Vizient is a health care performance improvement company that manages a database for retrospective performance improvement and research purposes compiled from member health systems, academic medical centers, and community hospitals geographically dispersed throughout the United States. 9 To analyze these trends, we plotted data using control charts.

We looked at both mortality, as a percent, and deaths per 1000 discharges for all discharges, discharges with acute respiratory failure (both intubated and nonintubated), and discharges without acute respiratory failure (to establish a baseline for non-COVID-19 related outcomes) using p Laney charts and u Laney charts, respectively. The data were subgrouped by month, beginning January 2017, and analyzed using QI Macros ® Version 2019.01. 12 P charts were selected for this classification data, and the p' or Laney charts were used to address overdispersion seen in control charts with large denominators. 13 During March and April, the first 2 months in which this COVID-19 ICD10 code was captured, the number of cases and deaths both sharply rose ( Figure 1A ). There was a large, concurrent decrease in the total number of patients who were not diagnosed with COVID-19, dropping over 200,000 discharges between February and April ( Figure 1B ). During these months, mortality from COVID-19 was also the highest it would be during the study period, peaking at 22% in March and 18% in April ( Figure 1A ). Mortality for patients not diagnosed with COVID-19 also rose slightly during this period, corresponding to the decrease in the total number of patients ( Figure 1B ).

Following this initial peak, the number of cases and deaths dropped to a nadir low in the summer months. This was accompanied by a drop in inpatient mortality for patients diagnosed with COVID-19, dropping to below 10% mortality in June. Both cases and deaths began rising again in October, November, and December but the mortality remained at around 10% despite an apparent worsening of the pandemic. Interestingly, the percentage of patients with COVID-19 intubated also decreased in a similar fashion. In March, 27% of COVID-19 cases were intubated. This fell to 8% of cases by June and remained low through the winter surge, decreasing to only 4% of discharges in December ( Figure S1 ).

We next looked at COVID-19 inpatient outcomes based on the region of the country. The number of COVID-19 cases and deaths varied widely across the United States. Initial peaks in COVID-19 cases occurred in April for New England, Mid-Atlantic, and the Midwest. In contrast, the initial peak of COVID-19 cases for the Southeast, Mid-Continent, and West occurred in July ( Figure S2 ). Despite this temporal difference in peak cases, the inpatient mortality for COVID-19 followed the same trend across the country. In all regions, mortality dropped below 10% in June and remained within 2% of this for the remainder of the year.

Using June as the inflection point, there was a significant difference (t = 6.45; p < 10 −5 ) in mortality before June (average 15.3% ± 4%) as compared to June and after (average 9.1% ± 1.7%). PHILLIPS ET AL. | 319

Regional surges, as measured by the percentage of a region's total COVID-19 cases (between March and December 2020) encountered at CBD hospitals in a given month, did not correlate with inpatient mortality (r = 0.19, p = 0.14). On a regional level, having "experience" with COVID-19 also did not seem to have an impact on inpatient mortality. Hospitals in all regions except for New England and the Mid-Atlantic had experienced between 23% and 26% of the total COVID-19 cases captured in this data set when mortality dropped below 10% in June ( Figure S3 ). In contrast, mortality in CDB hospitals in New England and the Mid-Atlantic dropped below 10% after having experienced 55% of their total cases. In sum, differences in the dynamics of the pandemic across CDB hospitals by region did not appear to influence the lethality of COVID-19.

Next, we explored how the addition of COVID-19 affected overall inpatient mortality. We expanded our analysis to include all discharges and 

The strain on the healthcare system during a pandemic and changes in human behavior both have the potential to change inpatient mortality by changing the patient population and level of care they seek out and receive. These changes can lead to increases in mortality from other diseases, as seen with acute cardiovascular mortality in England and Wales. 14 To see if this was true in our data, we next investigated whether the increased all-cause mortality was secondary to an increase in the mortality from respiratory failure, as seen in nearly all COVID-19 hospital admissions, or if the increased mortality was spread across other diseases as well. 3 Between January 2017 and December 2020, there was a steady increase in the percentage of hospital admissions in which the ICD10 code of acute respiratory failure was captured ( Figure S5 ). Over this same period, control charts of hospital mortality and death rate (per 1000 admissions) display special cause variation for the periods of January 2017 to April 2019. Interestingly, the mortality and death rate do not increase from the prepandemic mean after March of 2020. There is special cause variation in April 2020 on both charts ( Figures 3A and S6) .

We next subdivided the acute respiratory failure data into those who required intubation and those who did not. Similar to patients with respiratory failure overall, those who did not require intubation also do not increase from the prepandemic mean after March of 2020, though both also had special cause variation in April 2020 with this data point outside the upper control limit (Figures 3B and S7 ). In patients with respiratory failure requiring intubation there is a striking increase in mortality, increasing 6% from the pre-COVID-19 baseline, and death rate which increases from 321 to 382 deaths per 1000 admissions ( Figures 3C and S8 ). In contrast with AHRF patients who were not intubated, there is a dramatic increase in mortality seen during November and December of 2020 in patients requiring intubation.

Interestingly, from March 2020 to December 2020, there was a marginal increase in the mean mortality from 1.02% to 1.41% and death rate from 10 per 1000 to 14 per 1000 of patients without respiratory failure as compared to prepandemic means, from January 2017 to February 2020 ( Figures 3D and S9) . There is again a special cause variation in April 2020, November 2020, and December 2020 on both charts with mortality and death rate exceeding the upper control limit, reflecting a spring and winter surge as seen with AHRF patients who required intubation.

Finally, we wanted to see if differences in outcomes by age contributed to the changing inpatient, all-cause mortality. Throughout 2020, even after the pandemic, the percentage of elderly patients over the age of 75 did not change compared to the previous 3 years ( Figure 4A ). The total number of admissions for patients over the age of 50 did not increase over the course of the pandemic either ( Figure S10 ). This age group did however have a more dramatic increase in mortality after March of 2020 and the onset of the COVID-19 pandemic leading to a relative increase in the number of elderly inpatient deaths ( Figure 4B ). Analyzing this data using p' Laney control charts, we find that the mean mortality for ages 18-30 increased marginally from 0.4% to 0.5%; without any special cause variation ( Figure 5A ). However, in the remaining age groups, the mean mortality increased from 0.9% to 1.2% for the 31-50 group with a special cause in April 2020, for ages 51-75, the mean mortality jumps from 2.5% to 3.4% with a similar special cause in April ( Figure 5B,C) . For the over One major variable that did change between March and June of 2020 was the medical community's understanding of, and therapeutic arsenal against, COVID-19. Data on the benefits of self-proning were published by late April. 15 Multiple publications espousing the survival benefits of therapeutic anticoagulation were published in early May. 16, 17 Preliminary results from the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial were released in mid-June, establishing steroids as the standard of care. 18 Since that time, further evidence has been published solidifying these interventions as effective at reducing mortality from COVID-19. [19] [20] [21] Other promising initial therapies, such as remdesivir, have since failed to show a significant mortality benefit and thus likely did not directly decrease inpatient mortality. 22,23 ACTT-1 did show a shorter time to discharge in the remdesivir group which potentially could have indirectly decreased overall inpatient mortality by increasing hospital resources for other patients. 22, 24 Other trials such as the WHO Solidarity Trial have failed to reproduce these results however and further study would be required to definitively prove this indirect effect on inpatient mortality from remdesivir. 25 Although no single advance would explain the dramatic fall in mortality, the sum of these separate practices and therapies likely leading to less severe disease. 26, 27 Although mortality for COVID-19 has fallen, the addition of a new disease with a 10% mortality has changed overall inpatient outcomes when compared to the prior 3 years. Overall inpatient mortality rose 30% from its prepandemic baseline leading to an additional 8 deaths per 1000 discharges. Interestingly, outcomes of patients with acute hypoxic respiratory failure did not experience an increase in mortality. Rather, patients with respiratory failure who also were intubated had much worse outcomes since the start of the pandemic than before, with mortality increasing 6% leading to 61 excess deaths per 1000 discharges.

Outcomes of intubated patients displayed a seasonality not seen in nonintubated patients, with a spike in mortality during November and December of 2020. This divergence could represent strain in hospital resources specific to the ICU. Multiple environmental and epidemiologic studies have shown that temperature and humidity can correlate with the severity of COVID-19. 28, 29 These environmental effects may manifest as worse outcomes in the most severe cases of COVID-19 although more research is needed to elucidate this potential relationship. Inpatient mortality increased for patients of all ages, but this increase was more pronounced for older patients, particularly those over the age of 75. The number of patients with respiratory failure who did not require intubation, after an initial spike, had returned to prepandemic baselines suggesting that the medical advances described above may have predominantly facilitated survival of patients not requiring intubation. There was a small increase in deaths for patients without respiratory failure as well, with 3 excess deaths per 1000 admits. Given the dramatic decline in the total number of admissions seen at the beginning of the pandemic, it is likely that only the sickest patients were being admitted to hospitals. 30 During COVID-19-related lockdowns in Italy, this self-selection likely caused significant increases in the mortality from endocrine conditions, such as complications of diabetes, and cardiovascular disease. 30 With patients avoiding the hospital, there would also be a dramatic delay in care for patients with diseases other than COVID-19. The increase in nonrespiratory failure mortality seen during both spring and winter surges could also be evidence that human behavior is exerting a selection bias where only the sickest patients are presenting to hospitals. In a nationwide analysis of cardiovascular deaths in England, one study found not only increased mortality but also that nearly half of these deaths occurred in the community suggesting delays in seeking help, likely secondary to COVID-19. 14 

Mortality associated with COVID-19 declined precipitously within the first few months of the pandemic. This decline seems to have been driven by an increased understanding of the disease and the advent of multiple new therapies for treating COVID-19. Despite the medical community's successes in reducing COVID-19 mortality to below 10%, this decline stagnated in the second half of 2020. Recent studies repurposing anticytokine medications, such as tocilizumab and baricitinib, in addition to the current standards of care, could potentially further reduce inpatient mortality from COVID-19. [32] [33] [34] [35] [36] Additionally, the percentage of patients with COVID-19 requiring intubation has fallen and widespread vaccination efforts are underway with vaccines effective at preventing severe disease. This will ultimately decrease the number of deaths in intubated patients with COVID-19 and thus reduce overall inpatient mortality.

The authors declare that there are no conflict of interests. 

The data that support the findings of this study are from the Vizient Clinical Data Base and are used with permission of Vizient, Inc. All rights reserved. Data are available for Vizient members at https:// www.vizientinc.com.

https://orcid.org/0000-0002-9329-5455

Provisional life expectancy estimates for

Declines in mortality over time for critically Ill adults with coronavirus disease 2019

Causes of death and comorbidities in hospitalized patients with COVID-19

Characteristics and clinical outcomes of 116,539 patients hospitalized with COVID-19-Poland

Risk for in-hospital complications associated with COVID-19 and influenza-veterans health administration, United States

Improving survival of critical care patients with coronavirus disease 2019 in England: a national cohort study

Trends in COVID-19 riskadjusted mortality rates

Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study

Debunking the July effect myth

Assessment of thirty-day readmission rate, timing, causes and predictors after hospitalization with COVID-19

Autopsy findings in 32 patients with COVID-19: a single-institution experience

The healthcare data guide: learning from data for improvement

Place and causes of acute cardiovascular mortality during the COVID-19 pandemic

Patient self-proning with high-flow nasal cannula improves oxygenation in COVID-19 pneumonia

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19

Dexamethasone in hospitalized patients with COVID-19-preliminary report

Dexamethasone in hospitalized patients with COVID-19

Association between administration of systemic corticosteroids and mortality among critically Ill patients with COVID-19: a meta-analysis

Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19

Remdesivir for the treatment of COVID-19-final report

Remdesivir for treatment of COVID-19; an updated systematic review and metaanalysis

Therapeutic interventions of remdesivir in diabetic and nondiabetic COVID-19 patients: a prospective observational study conducted on Pakistani population

Repurposed antiviral drugs for COVID-19-Interim WHO solidarity trial results

Surgical mask partition reduces the risk of noncontact transmission in a golden Syrian hamster model for coronavirus disease 2019 (COVID-19)

Pathogenesis and transmission of SARS-CoV-2 in golden hamsters

Effects of temperature variation and humidity on the death of COVID-19 in Wuhan

The association between ambient temperature and mortality of the coronavirus disease 2019 (COVID-19) in Wuhan, China: a time-series analysis

Non-COVID-19 patients in times of pandemic: emergency department visits, hospitalizations and cause-specific mortality in Northern Italy

Where are all the patients? Addressing COVID-19 fear to encourage sick patients to seek emergency care. NEJM Catalyst

Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial

Interleukin-6 receptor antagonists in critically Ill patients with COVID-19

Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis

Baricitinib plus remdesivir for hospitalized adults with COVID-19

Baricitinib plus standard of care for hospitalized adults with COVID-19

Effect of mortality from COVID-19 on inpatient outcomes